| SEI price and shares snapshot | $51.41 close on July 31, 2026 with $51.56 after hours; 76.42 million shares outstanding | StockAnalysis.com SEI quote and statistics | August 3, 2026 |
| Market capitalization | $3.93 billion, verified as $51.41 x 76.42 million shares with financial_rigor.py (0.03% deviation) | financial_rigor.py market-cap verification and StockAnalysis.com | August 3, 2026 |
| Q1 2026 revenue | $196.24 million, up 55% year over year, matching SEC EDGAR XBRL (196239000) from the Q1 2026 Form 10-Q | Q1 2026 Form 10-Q and SEC EDGAR XBRL | August 3, 2026 |
| Q1 2026 earnings and EBITDA | Consolidated net income of $32.06 million, net income attributable to Solaris of $21.44 million, adjusted pro forma net income of $39.39 million or $0.44 per fully diluted share, and adjusted EBITDA of about $84 million up 22% sequentially | Q1 2026 earnings release and Q1 2026 Form 10-Q | April 27, 2026 |
| Q2 2026 guidance | Q2 2026 adjusted EBITDA guidance raised to $83 million to $93 million from $76 million to $84 million, with Q3 2026 guidance of $80 million to $95 million | Q1 2026 earnings release guidance update | April 27, 2026 |
| FY2025 revenue | $622.21 million, up 98.7% from $313.09 million, cross-checked across StockAnalysis.com and SEC EDGAR XBRL | StockAnalysis.com financials and SEC EDGAR XBRL 10-K | August 3, 2026 |
| TTM financials | TTM revenue of $692.11 million, net income of $44.53 million, EPS of $0.86, operating income of $163.89 million, and EBITDA of $252.87 million | StockAnalysis.com statistics | August 3, 2026 |
| Balance sheet | Cash and cash equivalents of $344.47 million and total debt of about $1.62 billion as of March 31, 2026, with long-term debt current portion of $319.7 million, long-term debt noncurrent of $395.4 million, and convertible notes of $881.6 million | Q1 2026 Form 10-Q and StockAnalysis.com balance sheet | August 3, 2026 |
| Net debt | Net debt of about -$1.27 billion, or -$16.66 per share, computed as $344.47 million cash minus $1.62 billion total debt | StockAnalysis.com statistics and Q1 2026 Form 10-Q | August 3, 2026 |
| Cash flow and capex | TTM operating cash flow of $262.40 million, capital expenditures of -$845.78 million, and free cash flow of -$583.39 million as the company invests heavily in equipment held for lease | StockAnalysis.com cash flow statement | August 3, 2026 |
| Valuation ratios | Trailing PE of 59.53, forward PE of 44.26, price/sales of 5.68, price/book of 3.84, EV of $5.20 billion, EV/Sales of 7.52, and EV/EBITDA of 20.57 | StockAnalysis.com statistics | August 3, 2026 |
| Share count and dilution | 76.42 million shares outstanding with shares up 87.6% year over year and 44.9% quarter over quarter, reflecting the Genco acquisition, convertible notes, and the 2,880,682 Class A shares issued for GESA on July 1, 2026 | StockAnalysis.com statistics and GESA 8-K | August 3, 2026 |
| GESA acquisition | Closed July 1, 2026 for about $55 million in cash plus 2,880,682 shares of Class A common stock, acquiring a full cycle power generation operations, maintenance, and technical solutions provider | GESA acquisition 8-K filed July 6, 2026 | August 3, 2026 |
| $1.3 billion senior notes | Issued $1.3 billion aggregate principal of 6.375% Senior Notes due 2031 on May 12, 2026, at par, for net proceeds of about $1.28 billion | 8-K filed May 12, 2026 | August 3, 2026 |
| Power capacity and backlog | Pro forma generation capacity of about 3,100 MW, a Stateline joint venture of about 900 MW, and three long-term contracts with investment-grade global technology customers totaling more than 2 GW of contracted generation capacity, including a 600+ MW, 10-year contract signed April 24, 2026 | Q1 2026 earnings release | April 27, 2026 |
| Segment results Q1 2026 | Power Solutions revenue of about $129 million up 24% sequentially with roughly 910 MW earning revenue, and Logistics Solutions revenue of about $68 million down 11% sequentially with 104 fully utilized systems | Q1 2026 earnings release | April 27, 2026 |
| Dividend | Quarterly dividend of $0.12 per share, about $0.48 annualized for a 0.93% yield, representing the 31st consecutive quarterly dividend when paid in June 2026 | Q1 2026 earnings release and StockAnalysis.com | August 3, 2026 |
| 52-week range and beta | $24.57 to $86.19 with beta of 1.18 and a 52-week price change of +54.6% | StockAnalysis.com statistics | August 3, 2026 |
| Short interest | 15.24 million shares short, about 19.94% of shares outstanding, 26.13% of float, and 5.27 days to cover | StockAnalysis.com statistics short selling | August 3, 2026 |
| Risk scores | Altman Z-Score of 1.03 and Piotroski F-Score of 5 | StockAnalysis.com statistics | August 3, 2026 |
| Analyst consensus | Buy with an average target of $94.34 across 14 analysts, low $80 and high $120, median $91.50 | StockAnalysis.com forecast and analyst ratings | July 22, 2026 |
| Analyst rating mix, July 2026 | 8 Strong Buy, 5 Buy, 1 Hold, 0 Sell out of 14 analysts | StockAnalysis.com forecast recommendation trends | July 22, 2026 |
| Recent analyst target updates | Morgan Stanley reiterates Buy $90 on July 22, Barclays reiterates Buy $86 on July 16, Northland reiterates Buy $104 on July 7, Wolfe Research initiates Buy $120 on July 6, and Needham initiates Buy $97 on June 29 | StockAnalysis.com analyst ratings | July 22, 2026 |
| Consensus financial forecast | FY2026 revenue estimate of $819.56 million up 31.7% with adjusted EPS of $1.15, and FY2027 revenue of $1.23 billion up 49.6% with adjusted EPS of $2.33 | StockAnalysis.com forecast financial forecast | July 22, 2026 |
| Index inclusion | SEI joined the S&P SmallCap 600 effective prior to the opening of trading on July 15, 2026, replacing Catalyst Pharmaceuticals | PRNewswire July 9, 2026 announcement | July 9, 2026 |
| Technical snapshot | 5-day SMA near $49.20, 20-day SMA near $60.68, 50-day SMA near $68.97, 100-day SMA near $67.27, 200-day SMA near $58.82, 14-day RSI near 37.77, 14-day ADX near 26.87, 14-day historic volatility near 114% | Barchart and StockAnalysis.com technical snapshots | August 3, 2026 |